Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Design of Bifunctional Dendritic 5-Aminolevulinic Acid and Hydroxypyridinone Conjugates for Photodynamic Therapy.

Zhou T, Battah S, Mazzacuva F, Hider RC, Dobbin P, MacRobert AJ.

Bioconjug Chem. 2018 Oct 17;29(10):3411-3428. doi: 10.1021/acs.bioconjchem.8b00574. Epub 2018 Oct 5.

2.

Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy.

Battah S, Hider RC, MacRobert AJ, Dobbin PS, Zhou T.

J Med Chem. 2017 Apr 27;60(8):3498-3510. doi: 10.1021/acs.jmedchem.7b00346. Epub 2017 Apr 6.

PMID:
28363026
3.

Resonance Raman Spectra of Five-Coordinate Heme-Nitrosyl Cytochromes c': Effect of the Proximal Heme-NO Environment.

Servid AE, McKay AL, Davis CA, Garton EM, Manole A, Dobbin PS, Hough MA, Andrew CR.

Biochemistry. 2015 Jun 2;54(21):3320-7. doi: 10.1021/acs.biochem.5b00227. Epub 2015 May 22.

PMID:
25961377
4.

Conformational control of the binding of diatomic gases to cytochrome c'.

Manole A, Kekilli D, Svistunenko DA, Wilson MT, Dobbin PS, Hough MA.

J Biol Inorg Chem. 2015 Jun;20(4):675-86. doi: 10.1007/s00775-015-1253-7. Epub 2015 Mar 20.

PMID:
25792378
5.

Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy.

Casas A, Battah S, Di Venosa G, Dobbin P, Rodriguez L, Fukuda H, Batlle A, MacRobert AJ.

J Control Release. 2009 Apr 17;135(2):136-43. doi: 10.1016/j.jconrel.2009.01.002. Epub 2009 Jan 12.

PMID:
19168101
6.

Cytochrome bd confers nitric oxide resistance to Escherichia coli.

Mason MG, Shepherd M, Nicholls P, Dobbin PS, Dodsworth KS, Poole RK, Cooper CE.

Nat Chem Biol. 2009 Feb;5(2):94-6. doi: 10.1038/nchembio.135. Epub 2008 Dec 21.

PMID:
19109594
7.

Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates.

Battah S, Balaratnam S, Casas A, O'Neill S, Edwards C, Batlle A, Dobbin P, MacRobert AJ.

Mol Cancer Ther. 2007 Mar;6(3):876-85.

8.

Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study.

Battah S, O'Neill S, Edwards C, Balaratnam S, Dobbin P, MacRobert AJ.

Int J Biochem Cell Biol. 2006;38(8):1382-92. Epub 2006 Mar 3.

PMID:
16546435
9.

Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells.

Rodriguez L, Batlle A, Di Venosa G, Battah S, Dobbin P, Macrobert AJ, Casas A.

Br J Pharmacol. 2006 Apr;147(7):825-33.

10.

Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy.

Di Venosa GM, Casas AG, Battah S, Dobbin P, Fukuda H, Macrobert AJ, Batlle A.

Int J Biochem Cell Biol. 2006 Jan;38(1):82-91. Epub 2005 Sep 6.

PMID:
16172016
12.

Characterization of the Shewanella oneidensis MR-1 decaheme cytochrome MtrA: expression in Escherichia coli confers the ability to reduce soluble Fe(III) chelates.

Pitts KE, Dobbin PS, Reyes-Ramirez F, Thomson AJ, Richardson DJ, Seward HE.

J Biol Chem. 2003 Jul 25;278(30):27758-65. Epub 2003 May 5.

13.
14.

Voltammetry of a flavocytochrome c(3): the lowest potential heme modulates fumarate reduction rates.

Butt JN, Thornton J, Richardson DJ, Dobbin PS.

Biophys J. 2000 Feb;78(2):1001-9.

15.

Open conformation of a flavocytochrome c3 fumarate reductase.

Bamford V, Dobbin PS, Richardson DJ, Hemmings AM.

Nat Struct Biol. 1999 Dec;6(12):1104-7.

PMID:
10581549
16.

Characterization of a flavocytochrome that is induced during the anaerobic respiration of Fe3+ by Shewanella frigidimarina NCIMB400.

Dobbin PS, Butt JN, Powell AK, Reid GA, Richardson DJ.

Biochem J. 1999 Sep 1;342 ( Pt 2):439-48.

17.

Dissimilatory Fe(III) reduction by Clostridium beijerinckii isolated from freshwater sediment using Fe(III) maltol enrichment.

Dobbin PS, Carter JP, Garcia-Salamanca San Juan C, von Hobe M, Powell AK, Richardson DJ.

FEMS Microbiol Lett. 1999 Jul 1;176(1):131-8.

18.

Crystallization and preliminary X-ray crystallographic analysis of a periplasmic tetrahaem flavocytochrome c3 from Shewanella frigidimarina NCIMB400 which has fumarate reductase activity.

Bamford V, Dobbin PS, Lee SC, Reilly A, Powell AK, Richardson DJ, Hemmings AM.

Acta Crystallogr D Biol Crystallogr. 1999 Jun;55(Pt 6):1222-5.

PMID:
10329791
19.

Structures of 3-hydroxy-1-(2-methoxyethyl)-2-methyl-4-pyridinone, its hydrochloride and 1-ethyl-3-hydroxy-2-methyl-4-pyridinone hydrochloride hydrate.

Xiao G, van der Helm D, Goerlitz FH, Hider RC, Dobbin PS.

Acta Crystallogr C. 1993 Sep 15;49 ( Pt 9):1646-9.

PMID:
8217022
20.

The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia.

Gower JD, Ambrose IJ, Manek S, Bright J, Dobbin PS, Hider RC, Goddard JG, Thorniley MS, Green CJ.

Agents Actions. 1993 Sep;40(1-2):96-105.

PMID:
8147275
21.

Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.

Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao G, van der Helm D.

J Med Chem. 1993 Aug 20;36(17):2448-58.

PMID:
8355246
22.

3-[1-(Ethylamino)ethylidene]-6-methyl-3H-pyran-2,4-dione.

Xiao G, Van Der Helm D, Hider RC, Dobbin PS.

Acta Crystallogr C. 1993 May 15;49 ( Pt 5):980-2.

PMID:
8347307
23.

Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.

Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, Hider RC.

Drug Metab Dispos. 1992 Mar-Apr;20(2):256-61.

PMID:
1352218
24.

Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.

Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC.

Blood. 1991 May 1;77(9):2049-53.

PMID:
2018841
25.
26.

The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators.

Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC.

Blood. 1991 Feb 1;77(3):637-43.

PMID:
1991172

Supplemental Content

Loading ...
Support Center